CA2937418A1 - Compositions and methods for treating intracerebral hemorrhage - Google Patents

Compositions and methods for treating intracerebral hemorrhage Download PDF

Info

Publication number
CA2937418A1
CA2937418A1 CA2937418A CA2937418A CA2937418A1 CA 2937418 A1 CA2937418 A1 CA 2937418A1 CA 2937418 A CA2937418 A CA 2937418A CA 2937418 A CA2937418 A CA 2937418A CA 2937418 A1 CA2937418 A1 CA 2937418A1
Authority
CA
Canada
Prior art keywords
ich
less
subject
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2937418A
Other languages
English (en)
French (fr)
Inventor
Steven ARKIN
Joachim Fruebis
Marcus E. Carr
Sunita HETT
Reema JASUJA
Debra D. Pittman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CA2937418A1 publication Critical patent/CA2937418A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2937418A 2014-01-24 2015-01-15 Compositions and methods for treating intracerebral hemorrhage Abandoned CA2937418A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461931071P 2014-01-24 2014-01-24
US61/931,071 2014-01-24
PCT/IB2015/050313 WO2015110939A1 (en) 2014-01-24 2015-01-15 Compositions and methods for treating intracerebral hemorrhage

Publications (1)

Publication Number Publication Date
CA2937418A1 true CA2937418A1 (en) 2015-07-30

Family

ID=52630418

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2937418A Abandoned CA2937418A1 (en) 2014-01-24 2015-01-15 Compositions and methods for treating intracerebral hemorrhage

Country Status (18)

Country Link
US (2) US20160375109A1 (enExample)
EP (1) EP3096779B1 (enExample)
JP (1) JP6624787B2 (enExample)
KR (3) KR20180014221A (enExample)
CN (2) CN112156176A (enExample)
AU (1) AU2015208819B2 (enExample)
BR (1) BR112016014617A2 (enExample)
CA (1) CA2937418A1 (enExample)
DK (1) DK3096779T3 (enExample)
ES (1) ES2772802T3 (enExample)
HU (1) HUE047588T4 (enExample)
IL (1) IL246637A0 (enExample)
MX (1) MX375355B (enExample)
PL (1) PL3096779T3 (enExample)
PT (1) PT3096779T (enExample)
RU (1) RU2016126423A (enExample)
SI (1) SI3096779T1 (enExample)
WO (1) WO2015110939A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2761730T3 (es) * 2013-01-31 2020-05-20 Pfizer Composiciones y procedimientos para contrarrestar la inhibición del factor Xa
EP3049434A1 (en) 2013-09-24 2016-08-03 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005123118A1 (en) * 2004-06-21 2005-12-29 Novo Nordisk Health Care Ag Use of factor viia or factor viia equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage (ich)
MX2008006313A (es) 2005-11-15 2008-11-06 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
JP2011509978A (ja) * 2008-01-18 2011-03-31 ノボ ノルディスク ヘルス ケア アーゲー 選択されたＩＣＨ患者亜集団における脳内出血（ＩＣＨ）後の出血拡大、及び／又は浮腫生成の予防又は減弱のための、第ＶＩＩａ因子又は第ＶＩＩａ因子等価物の使用
ES2605801T3 (es) * 2009-07-15 2017-03-16 Portola Pharmaceuticals, Inc. Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia
WO2011020866A2 (en) * 2009-08-20 2011-02-24 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
US9371522B2 (en) * 2011-09-30 2016-06-21 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
WO2014018120A1 (en) * 2012-07-25 2014-01-30 Catalyst Biosciences, Inc. Modified factor x polypeptides and uses thereof
ES2761730T3 (es) * 2013-01-31 2020-05-20 Pfizer Composiciones y procedimientos para contrarrestar la inhibición del factor Xa

Also Published As

Publication number Publication date
EP3096779B1 (en) 2019-12-18
US20190231856A1 (en) 2019-08-01
RU2016126423A (ru) 2018-03-01
AU2015208819B2 (en) 2020-01-23
ES2772802T3 (es) 2020-07-08
MX2016009665A (es) 2016-11-14
JP2015147764A (ja) 2015-08-20
HUE047588T4 (hu) 2020-06-29
EP3096779A1 (en) 2016-11-30
US20160375109A1 (en) 2016-12-29
IL246637A0 (en) 2016-08-31
DK3096779T3 (da) 2020-02-24
AU2015208819A1 (en) 2016-06-30
WO2015110939A1 (en) 2015-07-30
KR20160093731A (ko) 2016-08-08
MX375355B (es) 2025-03-04
CN112156176A (zh) 2021-01-01
KR20210008177A (ko) 2021-01-20
PL3096779T3 (pl) 2020-05-18
BR112016014617A2 (pt) 2017-09-19
SI3096779T1 (sl) 2020-03-31
KR20180014221A (ko) 2018-02-07
RU2016126423A3 (enExample) 2018-03-01
JP6624787B2 (ja) 2019-12-25
HUE047588T2 (hu) 2020-04-28
CN105934250A (zh) 2016-09-07
PT3096779T (pt) 2020-02-21

Similar Documents

Publication Publication Date Title
US20220298261A1 (en) Serpinf2-Binding Molecules and Method of Use Thereof
TW200817033A (en) Method of treating stroke with thrombolytic agent
JP6514893B2 (ja) 止血を調節するための組成物および方法
US9732334B2 (en) Mutated tissue plasminogen activators and uses thereof
US20190231856A1 (en) Compositions and methods for treating intracerebral hemorrhage
JP6629744B2 (ja) 第Ｘａ因子の半減期を延ばす組成物および方法
JP2022519327A (ja) 頭蓋内出血の治療方法及び効果の評価方法
HK40040435A (en) Compositions and methods for treating intracerebral hemorrhage
WO2023147574A2 (en) Compositions and methods for treating factor ix deficiency
KR20230147138A (ko) Adamts13 변이체
HK1228257A1 (en) Compositions and methods for treating intracerebral hemorrhage
JP7515557B2 (ja) 凝固異常を伴う敗血症の治療及び／又は改善のための医薬
US20250302927A1 (en) Modified factor xa polypeptides and methods of use
WO2026076443A1 (en) Methods for treating factor x deficiency
US11085031B2 (en) Thrombin-thrombomodulin fusion proteins as a powerful anticoagulant
HK40059596A (en) Drug for treating and/or improving septicemia associated with coagulation abnormality
JP2006180840A (ja) 血栓の溶解を亢進させるポリペプチド及びその利用
HK1196289A1 (zh) 用於败血症的治疗和/或改善的药物
HK1196289B (en) Medicine for treatment and/or improvement of sepsis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160720

FZDE Discontinued

Effective date: 20230329